OBJECTIVE: To investigate whether compliance during the first 2 years of statin therapy is associated with reduced hospitalization rates and direct medical costs during year 3. STUDY DESIGN: An integrated pharmacy and medical claims database was used to identify adult patients with a new statin prescription between July 1, 2001, and June 30, 2002. The study tracked statin prescription refills during the first 2 years after the initial statin claim and tracked hospitalizations and direct medical costs during the first 3 years. METHODS: Patients were stratified according to compliance in the first 2 years using the medication possession ratio, where 80% or higher is compliant and less than 80% is noncompliant. The relationship between compliance rates and direct medical costs was evaluated using a generalized linear model. Adjusting for covariates that may affect cardiovascular risk, the relationship between compliance and the likelihood of hospitalization was assessed using logistic regression models. RESULTS: The 2-year medication possession ratio was 80% or higher in 3512 patients (compliant) and was less than 80% in 6715 patients (noncompliant). Compared with the noncompliant patients, the compliant patients during year 3 had significantly fewer hospitalizations (16% vs 19%) and lower total direct medical costs (excluding the cost of statin therapy) ($4040 vs $4908 per patient) (P <.01 for both). CONCLUSION: Compliance with statin therapy in the first 2 years of use may reduce hospitalization rates and direct medical costs in the subsequent year.
OBJECTIVE: To investigate whether compliance during the first 2 years of statin therapy is associated with reduced hospitalization rates and direct medical costs during year 3. STUDY DESIGN: An integrated pharmacy and medical claims database was used to identify adult patients with a new statin prescription between July 1, 2001, and June 30, 2002. The study tracked statin prescription refills during the first 2 years after the initial statin claim and tracked hospitalizations and direct medical costs during the first 3 years. METHODS:Patients were stratified according to compliance in the first 2 years using the medication possession ratio, where 80% or higher is compliant and less than 80% is noncompliant. The relationship between compliance rates and direct medical costs was evaluated using a generalized linear model. Adjusting for covariates that may affect cardiovascular risk, the relationship between compliance and the likelihood of hospitalization was assessed using logistic regression models. RESULTS: The 2-year medication possession ratio was 80% or higher in 3512 patients (compliant) and was less than 80% in 6715 patients (noncompliant). Compared with the noncompliant patients, the compliant patients during year 3 had significantly fewer hospitalizations (16% vs 19%) and lower total direct medical costs (excluding the cost of statin therapy) ($4040 vs $4908 per patient) (P <.01 for both). CONCLUSION: Compliance with statin therapy in the first 2 years of use may reduce hospitalization rates and direct medical costs in the subsequent year.
Authors: Andrew M Davis; Michael S Taitel; Jenny Jiang; Dima M Qato; Monica E Peek; Chia-Hung Chou; Elbert S Huang Journal: J Racial Ethn Health Disparities Date: 2016-06-28
Authors: Amy Davidoff; Ruth Lopert; Bruce Stuart; Thomas Shaffer; Jennifer T Lloyd; J Samantha Shoemaker Journal: Value Health Date: 2012-04-10 Impact factor: 5.725
Authors: Patrick J O'Connor; Julie A Schmittdiel; Ram D Pathak; Ronald I Harris; Katherine M Newton; Kris A Ohnsorg; Michele Heisler; Andrew T Sterrett; Stanley Xu; Wendy T Dyer; Marsha A Raebel; Abraham Thomas; Emily B Schroeder; Jay R Desai; John F Steiner Journal: Diabetes Care Date: 2014-10-14 Impact factor: 19.112
Authors: Zoltan Kiss; Laszlo Nagy; Istvan Reiber; György Paragh; Mark Peter Molnar; György Rokszin; Zsolt Abonyi-Toth; Laszlo Mark Journal: Arch Med Sci Date: 2013-05-27 Impact factor: 3.318